386 related articles for article (PubMed ID: 12867223)
21. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
22. Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy.
Sathiyakumar V; Park J; Golozar A; Lazo M; Quispe R; Guallar E; Blumenthal RS; Jones SR; Martin SS
Circulation; 2018 Jan; 137(1):10-19. PubMed ID: 29038168
[TBL] [Abstract][Full Text] [Related]
23. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
24. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
25. Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines.
Superko HR; Williams PT; Dansinger M; Schaefer E
Clin Cardiol; 2019 Jan; 42(1):101-110. PubMed ID: 30444024
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia.
Knopp RH; Frohlich J; Jokubaitis LA; Dawson K; Broyles FE; Gomez-Coronado D
Am J Med; 1994 Jun; 96(6A):69S-78S. PubMed ID: 8017470
[TBL] [Abstract][Full Text] [Related]
27. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group.
Wilson PWF; Jacobson TA; Martin SS; Jackson EJ; Le NA; Davidson MH; Vesper HW; Frikke-Schmidt R; Ballantyne CM; Remaley AT
J Clin Lipidol; 2021; 15(5):629-648. PubMed ID: 34802986
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Aguilar-Salinas CA; Gómez-Pérez FJ; Posadas-Romero C; Vázquez-Chávez C; Meaney E; Gulías-Herrero A; Guillén LE; Alvarado Vega A; Mendoza Pérez E; Eduardo Romero-Nava L; Angélica Gómez-Díaz R; Salinas-Orozco S; Moguel R; Novoa G
Atherosclerosis; 2000 Oct; 152(2):489-96. PubMed ID: 10998478
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
Ballantyne CM; Stein EA; Paoletti R; Southworth H; Blasetto JW
Am J Cardiol; 2003 Mar; 91(5A):25C-27C; discussion 28C. PubMed ID: 12646342
[TBL] [Abstract][Full Text] [Related]
30. A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting(estudio del control de las hiperlipidemiasen atención primaria): the cheap study.
Gómez-Gerique JA; Alvarez-Sala LA; Armada B; Fernández-Arias I; Martinez J; Hernández G;
Curr Ther Res Clin Exp; 2003 Jun; 64(6):338-54. PubMed ID: 24944383
[TBL] [Abstract][Full Text] [Related]
31. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
32. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
33. Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus.
Kim JY; Choi J; Kim SG; Kim NH
Diabetes Metab J; 2023 Nov; 47(6):837-845. PubMed ID: 37915183
[TBL] [Abstract][Full Text] [Related]
34. Nonfasting versus fasting lipid profile for cardiovascular risk prediction.
Langsted A; Nordestgaard BG
Pathology; 2019 Feb; 51(2):131-141. PubMed ID: 30522787
[TBL] [Abstract][Full Text] [Related]
35. Plasma fasting and nonfasting triglycerides and high-density lipoprotein cholesterol in atherosclerotic stroke: different profiles according to low-density lipoprotein cholesterol.
Kim SJ; Park YG; Kim JH; Han YK; Cho HK; Bang OY
Atherosclerosis; 2012 Aug; 223(2):463-7. PubMed ID: 22683121
[TBL] [Abstract][Full Text] [Related]
36. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
37. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization.
Valuck RJ; Williams SA; MacArthur M; Saseen JJ; Nair KV; McCollum M; Ensor JE
Clin Ther; 2003 Nov; 25(11):2936-57. PubMed ID: 14693317
[TBL] [Abstract][Full Text] [Related]
38. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
40. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
